Patents by Inventor Katharine HSU

Katharine HSU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for typing KIR2DL alleles
    Patent number: 11453908
    Abstract: Disclosed herein are methods and compositions such as primers, primer pairs, and kits for typing KIR2DL1, KIR2DL2, Sand KIR2DL3 alleles. The compositions and methods disclosed herein are useful in the selection of most appropriate donors for HCT.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 27, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Katharine Hsu, Jean-Benoit Le Luduec
  • Anti-KIR3DL1 antibodies
    Patent number: 11117964
    Abstract: The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 14, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Katharine Hsu, Nai-Kong V. Cheung, Su Yan, Yiyang Xu, Jingyi Xiang, Cheng Liu
  • KIR3DL1/HLA-B SUBTYPES FOR HEMATOPOIETIC CELL TRANSPLANTATION DONOR SELECTION
    Publication number: 20210161965
    Abstract: The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific combination of KIR3DL1 and HLA-B alleles. Also disclosed herein are methods for protecting a leukemia patient recipient from leukemic relapse following allogeneic hematopoietic cell transplantation (HCT).
    Type: Application
    Filed: March 9, 2018
    Publication date: June 3, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventor: Katharine Hsu
  • Methods and algorithm for selecting allogenic hematopoietic cell donor based on KIR and HLA genotypes
    Patent number: 10621188
    Abstract: This disclosure is directed to a method for scoring and ranking candidate HLA-compatible unrelated hematopoietic cell donors (URD) for patients with AML or myelodysplastic syndrome. Candidate donors are scored based on KIR/HLA allele and genotype combinations. The method disclosed herein permits ranking and selection of advantageous donors that predict improved clinical outcomes of hematopoietic stem cell transplantation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 14, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: Katharine Hsu
  • ANTI-KIR3DL1 ANTIBODIES
    Publication number: 20200031927
    Abstract: The disclosure provides antibody agents that bind to inhibitory human killer immunoglobulin-like receptors (KIRs). Particular antibody agents of the disclosure include antibody agents that bind to KIR3DL1 (also known as CD158e). Also provided are related nucleic acids, vectors, compositions and methods of using KIR-binding antibody agents of the present technology.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 30, 2020
    Applicants: Memorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
    Inventors: Katharine HSU, Nai-Kong V. Cheung, Su YAN, Yiyang XU, Jingyi XIANG, Cheng LIU
  • Donor and subtypes and leukemia control in HLA-compatible allogenic hematopoietic stem cell transplantation
    Patent number: 10407727
    Abstract: This disclosure generally relates to donor selection for hematopoietic stem cell transplantation. In particular, this disclosure relates to typing KIR3DL1 and HLA-B alleles as basis for donor selection.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: September 10, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: Katharine Hsu
  • METHODS AND KITS FOR TYPING KIR2DL ALLELES
    Publication number: 20190226017
    Abstract: Disclosed herein are methods and compositions such as primers, primer pairs, and kits for typing KIR2DL1, KIR2DL2, and KIR2DL3 alleles. The compositions and methods disclosed herein are useful in the selection of most appropriate donors for HCT.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Katharine HSU, Jean-Benoit LE LUDUEC
  • KIR3DL1 allele classification kit and method
    Patent number: 9963742
    Abstract: Disclosed herein are single nucleotide polymorphisms (SNPs) characteristic of functional subgroups of KIR3DL1. Also disclosed herein are methods for classifying KIR3DL1 alleles by using a series of oligonucleotide primers and PCR reaction conditions uniquely designed to identify group-specific SNPs from genomic DNA. The compositions and methods disclosed herein are useful in clinical settings and research laboratories, and enable prospective assessment of prognoses of various diseases and selection of most appropriate donors for HCT.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Katharine Hsu, Jeanette Boudreau
  • KIR3DL1 ALLELE CLASSIFICATION KIT AND METHOD
    Publication number: 20160040237
    Abstract: Disclosed herein are single nucleotide polymorphisms (SNPs) characteristic of functional subgroups of KIR3DL1. Also disclosed herein are methods for classifying KIR3DL1 alleles by using a series of oligonucleotide primers and PCR reaction conditions uniquely designed to identify group-specific SNPs from genomic DNA. The compositions and methods disclosed herein are useful in clinical settings and research laboratories, and enable prospective assessment of prognoses of various diseases and selection of most appropriate donors for HCT.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 11, 2016
    Inventors: Katharine HSU, Jeanette BOUDREAU
  • METHODS AND ALGORITHM FOR SELECTING ALLOGENIC HEMATOPOIETIC CELL DONOR BASED ON KIR AND HLA GENOTYPES
    Publication number: 20160034666
    Abstract: This disclosure is directed to a method for scoring and ranking candidate HLA-compatible unrelated hematopoietic cell donors (URD) for patients with AML or myelodysplastic syndrome. Candidate donors are scored based on KIR/HLA allele and genotype combinations. The method disclosed herein permits ranking and selection of advantageous donors that predict improved clinical outcomes of hematopoietic stem cell transplantation.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventor: Katharine HSU
  • DONOR KIR3DL1 AND HLA-B SUBTYPES AND LEUKEMIA CONTROL IN HLA-COMPATIBLE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Publication number: 20150361506
    Abstract: This disclosure generally relates to donor selection for hematopoietic stem cell transplantation. In particular, this disclosure relates to typing KIR3DL1 and HLA-B alleles as basis for donor selection.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 17, 2015
    Inventor: Katharine HSU